RBPJ is a novel target for rhabdomyosarcoma therapy

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Nagao, Hiroko ^a   Setoguchi, Takao ^a   Kitamoto, Sho ^a   Ishidou, Yasuhiro ^a   Nagano, Satoshi ^a   Yokouchi, Masahiro ^a   Abematsu, Masahiko ^a   Kawabata, Naoya ^a   Maeda, Shingo ^a   Yonezawa, Suguru ^a   Komiya, Setsuro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN E; GAMMA SECRETASE INHIBITOR; KI 67 ANTIGEN; NOTCH RECEPTOR; PROTEIN P21; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RBPJ; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GENE ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; RNA INTERFERENCE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; DIBENZAZEPINES; DIPEPTIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; MICE; MICE, NUDE; RECEPTORS, NOTCH; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863619453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039268     Document Type: Article

References (49)

1. Wachtel M, Schafer BW, (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318-327.
2. Rodeberg D, Paidas C, (2006) Childhood rhabdomyosarcoma. Semin Pediatr Surg 15: 57-62.
3. Wachtel M, Schafer BW, (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318-327.
4. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, et al. (2011) Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 118: 1130-1137.
5. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, et al. (2011) Rhabdomyosarcoma in Children: A SEER Population Based Study. J Surg Res 170: e243-e251.
6. Ranganathan P, Weaver KL, Capobianco AJ, (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11: 338-351.
7. Leong KG, Karsan A, (2006) Recent insights into the role of Notch signaling in tumorigenesis. Blood 107: 2223-2233.
8. Fiuza UM, Arias AM, (2007) Cell and molecular biology of Notch. J Endocrinol 194: 459-474.
9. Bray SJ, (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7: 678-689.
10. Gordon WR, Arnett KL, Blacklow SC, (2008) The molecular logic of Notch signaling-a structural and biochemical perspective. J Cell Sci 121: 3109-3119.
11. Kopan R, Ilagan MX, (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
12. Allenspach EJ, Maillard I, Aster JC, Pear WS, (2002) Notch signaling in cancer. Cancer Biol Ther 1: 466-476.
13. Radtke F, Raj K, (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3: 756-767.
14. Nickoloff BJ, Osborne BA, Miele L, (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-6608.
15. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, et al. (1996) Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 16: 952-959.
16. Strobl LJ, Hofelmayr H, Stein C, Marschall G, Brielmeier M, et al. (1997) Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology 198: 299-306.
17. Aster JC, Blacklow SC, Pear WS, (2010) Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223: 262-273.
18. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, et al. (2009) Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 69: 458-465.
19. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, et al. (2009) Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957-1965.
20. Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, et al. (2011) Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One 6: e16234.
21. Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, et al. (2011) Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep 26: 1337-1342.
22. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, et al. (2011) Role of GLI2 in the growth of human osteosarcoma. J Pathol 224: 169-179.
23. Kawabata N, Ijiri K, Ishidou Y, Yamamoto T, Nagao H, et al. (2011) Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth. Int J Oncol 39: 899-906.
24. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, et al. (2010) The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep 23: 677-684.
25. Han J, Ma I, Hendzel MJ, Allalunis-Turner J, (2009) The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res 11: R57.
26. Ni CY, Murphy MP, Golde TE, Carpenter G, (2001) gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181.
27. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, et al. (2002) A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. Embo J 21: 1948-1956.
28. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2: 428-434.
29. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
30. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, et al. (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15: 2291-2301.
31. Stylianou S, Clarke RB, Brennan K, (2006) Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517-1525.
32. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, et al. (2011) Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol 224: 448-460.
33. Kuroda K, Tani S, Tamura K, Minoguchi S, Kurooka H, et al. (1999) Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem 274: 7238-7244.
34. Hirsinger E, Malapert P, Dubrulle J, Delfini MC, Duprez D, et al. (2001) Notch signalling acts in postmitotic avian myogenic cells to control MyoD activation. Development 128: 107-116.
35. Roma J, Masia A, Reventos J, Sanchez de Toledo J, Gallego S, (2011) Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 17: 505-513.
36. Belyea BC, Naini S, Bentley RC, Linardic CM, (2011) Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis. Clin Cancer Res 17: 7324-7336.
37. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66: 602-604.
38. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, et al. (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963.
39. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, et al. (2006) Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res 30: 1385-1390.
40. Beel AJ, Sanders CR, (2008) Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 65: 1311-1334.
41. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP, (2004) Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J 23: 1155-1165.
42. Sarmento LM, Huang H, Limon A, Gordon W, Fernandes J, et al. (2005) Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med 202: 157-168.
43. Abbas T, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414.
44. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
45. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, et al. (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70: 9937-9948.
46. Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, et al. (2009) Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 101: 2030-2037.
47. Sana J, Zambo I, Skoda J, Neradil J, Chlapek P, et al. (2011) CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol 34: 1-16.
48. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, et al. (2011) CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 6: e19506.
49. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, et al. (2010) The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 16: 6060-6070.